It is still unclear the type of genetic alterations that patients with breast cancer have and (1) whether these alterations are different or similar to patients with familial history of breast cancer and (2) whether these changes occur in pre-malignant lesions, and whether any of these genetic changes have any prognostic implication. Utilizing paraffin-embedded material and following the technique described by Sukpanichnant, we will search by PCR amplification for a variety of genetic alterations. Specifically LOH at 17p, a known locus for p53 mutations will be evaluated in a group of patients with known aggressive disease and poor outcome.
| Rodriguez-Canales, J; Hanson, J C; Tangrea, M A et al. (2007) Identification of a unique epigenetic sub-microenvironment in prostate cancer. J Pathol 211:410-9 |
| Wei, M-H; Toure, O; Glenn, G M et al. (2006) Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet 43:18-27 |
| Torres-Cabala, Carlos; Bibbo, Marluce; Panizo-Santos, Angel et al. (2006) Proteomic identification of new biomarkers and application in thyroid cytology. Acta Cytol 50:518-28 |
| Schmidt, Laura S; Nickerson, Michael L; Warren, Michelle B et al. (2005) Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dube syndrome. Am J Hum Genet 76:1023-33 |
| Pak, Ho; Gourgiotis, Loukas; Chang, Wen-I et al. (2003) Role of metastasectomy in the management of thyroid carcinoma: the NIH experience. J Surg Oncol 82:10-8 |
